234 related articles for article (PubMed ID: 30079133)
1. Associations between nonalcoholic fatty liver disease and ischemic stroke.
Alkagiet S; Papagiannis A; Tziomalos K
World J Hepatol; 2018 Jul; 10(7):474-478. PubMed ID: 30079133
[TBL] [Abstract][Full Text] [Related]
2. Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome.
Tziomalos K; Giampatzis V; Bouziana SD; Spanou M; Papadopoulou M; Pavlidis A; Kostaki S; Bozikas A; Savopoulos C; Hatzitolios AI
World J Hepatol; 2013 Nov; 5(11):621-6. PubMed ID: 24303090
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome.
Abdeldyem SM; Goda T; Khodeir SA; Abou Saif S; Abd-Elsalam S
J Clin Lipidol; 2017; 11(4):915-919. PubMed ID: 28579247
[TBL] [Abstract][Full Text] [Related]
4. The nonalcoholic fatty liver risk in prediction of unfavorable outcome after stroke: A nationwide registry analysis.
Chen K; Pan Y; Xiang X; Meng X; Yao D; Lin L; Li X; Wang Y;
Comput Biol Med; 2023 May; 157():106692. PubMed ID: 36924734
[TBL] [Abstract][Full Text] [Related]
5. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander.
Vanni E; Marengo A; Mezzabotta L; Bugianesi E
Semin Liver Dis; 2015 Aug; 35(3):236-49. PubMed ID: 26378641
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes.
Mantovani A; Mingolla L; Rigolon R; Pichiri I; Cavalieri V; Zoppini G; Lippi G; Bonora E; Targher G
Int J Cardiol; 2016 Dec; 225():387-391. PubMed ID: 27768965
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease as a multi-systemic disease.
Fotbolcu H; Zorlu E
World J Gastroenterol; 2016 Apr; 22(16):4079-90. PubMed ID: 27122660
[TBL] [Abstract][Full Text] [Related]
8. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
[TBL] [Abstract][Full Text] [Related]
10. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease.
Iqbal U; Perumpail BJ; Akhtar D; Kim D; Ahmed A
Medicines (Basel); 2019 Mar; 6(1):. PubMed ID: 30889791
[TBL] [Abstract][Full Text] [Related]
11. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations.
Kumar R; Priyadarshi RN; Anand U
J Clin Transl Hepatol; 2020 Mar; 8(1):76-86. PubMed ID: 32274348
[TBL] [Abstract][Full Text] [Related]
13. Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study.
Weinstein G; Zelber-Sagi S; Preis SR; Beiser AS; DeCarli C; Speliotes EK; Satizabal CL; Vasan RS; Seshadri S
JAMA Neurol; 2018 Jan; 75(1):97-104. PubMed ID: 29159396
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
15. Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?
Choudhary NS; Duseja A
J Clin Exp Hepatol; 2019; 9(4):506-514. PubMed ID: 31516267
[TBL] [Abstract][Full Text] [Related]
16. Acute Coronary Syndromes and Nonalcoholic Fatty Liver Disease: "Un Affaire de Coeur".
Ismaiel A; Popa SL; Dumitrascu DL
Can J Gastroenterol Hepatol; 2020; 2020():8825615. PubMed ID: 33313020
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Wong T; Wong RJ; Gish RG
Gastroenterol Hepatol (N Y); 2019 Feb; 15(2):83-89. PubMed ID: 31011302
[TBL] [Abstract][Full Text] [Related]
18. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.
Mikolasevic I; Milic S; Racki S; Zaputovic L; Stimac D; Radic M; Markic D; Orlic L
Perit Dial Int; 2016; 36(4):427-32. PubMed ID: 26475841
[TBL] [Abstract][Full Text] [Related]
20. Nonobese Fatty Liver Disease.
Kim D; Kim WR
Clin Gastroenterol Hepatol; 2017 Apr; 15(4):474-485. PubMed ID: 27581063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
